GlaxoSmithKline Pharmaceuticals (BOM:500660) ROCE % : 14.54% (As of Dec. 2023)

View and export this data going back to 1991. Start your Free Trial

What is GlaxoSmithKline Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. GlaxoSmithKline Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2023 was 14.54%.

GlaxoSmithKline Pharmaceuticals ROCE % Historical Data

The historical data trend for GlaxoSmithKline Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlaxoSmithKline Pharmaceuticals ROCE % Chart

GlaxoSmithKline Pharmaceuticals Annual Data

Trend

Dec13

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

ROCE %

Get a 7-Day Free Trial

28.44

13.64

23.64

33.27

33.97

GlaxoSmithKline Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															52.17	38.12	36.25	66.27	14.54

GlaxoSmithKline Pharmaceuticals ROCE % Calculation

GlaxoSmithKline Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Mar. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2023 )		(A: Mar. 2022 )		(A: Mar. 2023 )
	=	8382.122	/	( ( (46332.778 - 16984.288)	+	(33265.848 - 13263.701) )	/ 2 )
	=	8382.122	/	( (29348.49	+	20002.147)	/ 2 )
	=	8382.122	/	24675.3185
	=	33.97 %

GlaxoSmithKline Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	2630	/	( ( (32702.1 - 14618.1)	+	(0 - 0) )	/ 1 )
	=	2630	/	( ( 18084	+	0 )	/ 1 )
	=	2630	/	18084
	=	14.54 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

GlaxoSmithKline Pharmaceuticals (BOM:500660) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

GlaxoSmithKline Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of GlaxoSmithKline Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

GlaxoSmithKline Pharmaceuticals (BOM:500660) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » GlaxoSmithKline Pharmaceuticals Ltd (BOM:500660) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

GLAXO:India

Address

Dr. Annie Besant Road, GSK House, Worli, Mumbai, MH, IND, 400 030

Website

https://www.gsk-india.com

GlaxoSmithKline Pharmaceuticals Ltd is an India-based subsidiary of GlaxoSmithKline plc. GSK India develops and manufactures medicines, vaccines, and consumer products. Its medicines portfolio includes prescription drugs for conditions that include asthma, infectious diseases, mental health, and digestion, as well as nonprescription nutrition and cosmetic products. Its vaccines product line includes treatments for conditions such as influenza, HPV, hepatitis, and measles. Its consumer healthcare products include Horlicks-brand packaged food and beverage powders among other retail products. The company derives most of its revenue from India.

GlaxoSmithKline Pharmaceuticals (BOM:500660) Headlines

No Headlines